Information  X 
Enter a valid email address



Tuesday 02 March, 2021


IXICO selected by Cyclerion for a new AD study

RNS Number : 7695Q
02 March 2021


("IXICO" or the "Company")


IXICO is selected by Cyclerion for a new Alzheimer's disease study


IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been selected by Cyclerion Therapeutics, Inc., a  new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease . For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL).


Alzheimer's disease (AD) is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families. With no available therapies to address the underlying disease pathology, new approaches are urgently needed, and biopharmaceutical companies are responding with innovations in clinical trials and treatment targets in their AD pipelines. This new study will be looking at the role of vascular pathology in AD, and more specifically, the potential of the NO-sGC-cGMP pathway as a target for new AD therapies. 


Whilst this contract does not change management's expectations of financial performance for the year, it adds to the Company's strong order book, further increases visibility of future revenues, and reflects an increasing diversification of the Company's client base.


Lammert Albers, Chief Commercial Officer of IXICO, commented: " IXICO is thrilled to be chosen by Cyclerion Therapeutics and take part in this important Alzheimer's disease trial. There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of this devastating disease. With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support potential treatments that one day may be in the hands of Alzheimer's patients worldwide."


Chris Wright, Chief Medical Officer at Cyclerion, said: "We are pleased to leverage IXICO's neuroimaging services in this new Alzheimer's disease study. With Cyclerion's mission to develop treatments that restore cognitive function, it is very important that our study is supported by world-class providers who are specialist experts in CNS and Alzheimer's disease clinical trials. We are delighted that IXICO will support us in measuring the impact of the trialled treatment."


For further information please contact:



+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales




Walbrook PR Ltd

+44 (0)20 7933 8780


Paul McManus / Lianne Cawthorne /

[email protected]

Alice Woodings





IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.


More information is available on   and follow us on Twitter @IxicOplc  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t